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Abstract: This study aims to explore the role and the possible underlying molecular mechanism of SNF5 in the pathogenesis of
rheumatoid arthritis (RA). MH7A cells were respectively transfected with pc-SNF5 (pcDNA3.1 containing the Brg1 coding sequence),
short hairpin RNA against SNF5 (shSNF5), and their negative controls (pcDNA3.1 and shNC). The alterations of SNF5 expression
were assessed by qRT-PCR and western blot analysis. MTT assay, flow cytometry, and western blot analysis were performed to evaluate
proliferation, apoptosis, and expression levels of p16 and JNK pathway associated proteins, respectively. Finally, the effect of SNF5
was verified in fibroblast-like synoviocytes (FLSs) obtained from a rat model with adjuvant-induced arthritis. Results showed that the
expression of SNF5 was increased in the pc-SNF5 group (P < 0.05) while it was decreased in the shSNF5 group (P < 0.05). Afterwards,
cell viability after transfection was reduced by SNF5 overexpression (P < 0.05, P < 0.01, or P < 0.001), whereas it was enhanced by SNF5
knockdown (P < 0.05 or P < 0.001). In terms of apoptosis, SNF5 overexpression promoted cell apoptosis (P < 0.01). The western blot
analysis showed that the phosphorylated levels of proteins involved in the JNK pathway were downregulated by SNF5 overexpression
while they were upregulated by SNF5 knockdown (P < 0.05, P < 0.01, or P < 0.001). However, the effect of SNF5 on the expression of
p16 was the opposite. Finally, the effect of SNF5 was validated in murine FLSs. In conclusion, SNF5 suppresses proliferation and induces
apoptosis of fibroblast-like cells through overexpression of p16 and suppression of the JNK pathway.
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1. Introduction
Eukaryotic cells respond to external stimuli through
expression of a particular subset of genes in a coordinated
fashion and modulation of an inactivated chromatin state
(Sansam et al., 2005; Ramirez-Carrozzi et al., 2006; Clapier
and Cairns, 2009; Euskirchen et al., 2011; Narlikar et al.,
2013; Kadoch and Crabtree, 2015). The chromatin state
is altered by several factors, including SWItch/sucrose
nonfermentable (SWI/SNF) which was first discovered
in Saccharomyces cerevisiae (Clapier and Cairns, 2009;
Narlikar et al., 2013). In mammals, the core complex of
SWI/SNF consists of Brm/SNF2α, Brg1/SNF2β, SNF5/
INI1/BAF47, and SWI3/BAF170/BAF155. Accumulating
evidence demonstrated that SNF5 is essential for the
chromatin remodeling function of SWI/SNF both in vivo
and in vitro (Sansam et al., 2005; Ramirez-Carrozzi et al.,
2006; Clapier and Cairns, 2009; Euskirchen et al., 2011;
Narlikar et al., 2013; Kadoch and Crabtree, 2015).
Rheumatoid arthritis (RA), a chronic inflammatory
condition, affects multiple joints and is characterized by
inflammatory changes in the synovial tissue, hyperplasia
* Correspondence: wushupeng0051@126.com

and damage to the cartilage, and destruction of the
underlying joint(s) (Choy and Panayi, 2001; Müllerladner
et al., 2005). In RA, inflammatory cells are recruited
and activated at the site of the affected joints. These
inflammatory cells release large amounts of cytokines
(inflammatory mediators), which facilitates extensive
proliferation of the synovial fibroblasts, ultimately
forming hyperplastic villous synovial tissues called pannus
(Müllerladner et al., 2005). Pannus releases inflammatory
mediators locally and is responsible for destruction of the
affected joints. Hence, inhibition of pannus formation
would suppress the progression of RA (Sherr and Roberts,
1995; Taniguchi et al., 1999; Nasu et al., 2001; Nonomura
et al., 2001, 2006; Nishida et al., 2004; Choi et al., 2005;
Murakami et al., 2012).
p16, a cyclin-dependent kinase inhibitor (CDKI), is
encoded by the CDKN2A gene. CDKIs play an important
role in cell cycle progression and upregulation of CDKIs
causes cell cycle arrest (Sherr and Roberts, 1995). Studies
have shown that adenoviral gene transfer of p16 led to the
suppression of fibroblasts in human RA synovial tissues
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without induction of apoptosis and the forced expression
of p16 ameliorated collagen-induced arthritis in mice
(Nasu et al., 2001) and adjuvant-induced arthritis in rats
(Nonomura et al., 2006).
Mitogen-activated protein kinase (MAPK), one of the
critical players in the pathogenesis of RA (Han et al., 1999;
Tournier et al., 2000; Barr and Bogoyevitch, 2001; Han,
2001; Piecyk and Anderson, 2001; Johnson and Lapadat,
2002), consists of three major families of MAPKs, namely
c-Jun-N terminal kinase (JNK), extracellular regulating
kinase (ERK), and p38 kinase (Han et al., 1999; Barr and
Bogoyevitch, 2001; Johnson and Lapadat, 2002). MAPKs
including JNKs are activated by phosphorylation of
threonine and tyrosine residues modulated by MAPK
kinases, which are in turn activated by MAPK kinase
kinases (MKKs). There are two isoforms of MKKs,
MKK4 and MKK7, of which MKK7 contributes to the
pathogenesis of RA through development of fibroblastlike synoviocytes (FLSs) (Han et al., 1999; Tournier et al.,
2000; Han, 2001).
Because of the increased incidence of toxicity and
limited efficacy of the current drugs prescribed for RA
(Roberts, 1998; Smolen and Steiner, 2003), the search for
novel drugs continues and therein lies the importance of
understanding the signaling pathways responsible in the
pathogenesis RA. To the best of our knowledge, this is the
first time to explore the role of SNF5 in the pathogenesis of
RA along with an understanding of the possible underlying
molecular mechanism.
2. Materials and methods
2.1. Cell culture
MH7A cells were obtained from the Riken Cell Bank
(Ibaraki, Japan). Cells were cultured in RPMI-1640 (Wako,
Osaka, Japan) supplemented with 10% heat-inactivated
fetal bovine serum (FBS), penicillin (final concentration:
100 U/mL), and streptomycin (final concentration: 0.1
mg/mL) in a humidified atmosphere of 5% CO2 and 95%
air at 37 °C (Nakayama et al., 2012).
2.2. Plasmids transfection
The SNF5 expression vector (pc-SNF5) was constructed by
subcloning the full-length wild-type Brg1 coding sequence
into pcDNA3.1 (+) and was confirmed by sequencing. The
empty pcDNA3.1 was transfected as a control (Xu et al.,
2010). The lentivirus target sequences for short hairpin
RNA (shRNA) against SNF5 (shSNF5) were designed as
sense, 5’-CAG ACC AGC GCG UCA UCA UdT dT-3’ and
antisense, 5’-AUG AUG ACG CGC UGG UCU GdT dT3’. shSNF5 and its negative control shRNA (shNC) were
synthesized by GenePharma Co. (Shanghai, China). Cell
transfections were conducted using the Lipofectamine
3000 reagent (Invitrogen, Carlsbad, CA, USA) according
to the manufacturer’s protocol. Stable SNF5 transfection
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was generated by selection under G418 (GIBCO, Paisley,
UK).
To summarize, there were four groups: the pcDNA3.1
group (MH7A cells transfected with the empty pcDNA3.1),
pc-SNF5 group (MH7A cells transfected with pc-SNF to
overexpress SNF5), shNC group (MH7A cells transfected
with shNC), and shSNF5 group (MH7A cells transfected
with shSNF5 to silence SNF5).
2.3. MTT assay
Cell
viability
was
determined
using
a
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) colorimetric assay according to standard
methods. Each experiment was performed three times.
2.4. Apoptosis assay
Apoptosis analysis was performed to identify and
quantify the apoptotic cells by using an annexin V-FITC/
PI apoptosis detection kit (Beijing Biosea Biotechnology,
Beijing, China). The MH7A cells (1 × 105 cells/well)
were seeded in a 6-well plate. Treated cells were washed
twice with cold phosphate-buffered saline (PBS) and
resuspended in binding buffer. The adherent and
floating cells were combined and treated according to
the manufacturer’s instructions and measured with a
flow cytometer (Beckman Coulter, Miami, FL, USA) to
differentiate apoptotic cells (annexin-V-positive and PInegative) from necrotic cells (annexin-V- and PI-positive).
2.5. Quantitative reverse-transcription PCR (qRT-PCR)
Total RNA was isolated from transfected cells by using the
TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and DNaseI
(Promega) (Gresh et al., 2005). Reverse transcription was
performed by using Multiscribe Reverse Transcriptase
(Applied Biosystems, Foster City, CA, USA) and random
hexamers or oligo(dT). The reverse transcription conditions
were 10 min at 25 °C, 30 min at 48 °C, and a final step of 5
min at 95 °C. The sequences of the primers were as follows:
SNF5 forward primer: 5’-CCT CTC TCA ACG CTG TCC
AAC TG-3’, reverse primer: 5’-ATC TTG GCG AGG ATG
TGC TTG TCT T-3’. GAPDH forward primer: 5’-GCA
CCG TCA AGG CTG AGA AC-3’, reverse primer: 5’-TGG
TGA AGA CGC CAG TGG A-3’.
2.6. Western blot analysis
Proteins were extracted using RIPA lysis buffer (Beyotime
Biotechnology, Shanghai, China) supplemented with
protease inhibitors (Roche, Guangzhou, China). The
proteins were quantified using the BCA Protein Assay Kit
(Pierce, Appleton, WI, USA). The western blot system was
established using a Bio-Rad Bis-Tris Gel System according
to the manufacturer’s instructions. Primary antibodies
against SNF5 (ab192864), total JNK (t-JNK, ab208035),
phosphorylated JNK (p-JNK, ab76572), total c-JUN (t-cJUN, ab119944), and p16 (ab51243) were purchased from
Abcam (Shanghai, China). Primary antibodies against total
MKK4 (t-MKK4, 9152), phosphorylated MKK4 (p-MKK4,
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9155), and phosphorylated c-JUN (p-c-JUN, 2993) were
purchased from Cell Signaling Technology (Beverly, MA,
USA). GAPDH antibody was purchased from Sigma
(G9545, St. Louis, MO, USA). Each primary antibody
was incubated with the membrane at 4 °C overnight,
followed by washing and incubation with secondary
antibodies marked by horseradish peroxidase for 1 h
at room temperature. After rinsing, the polyvinylidene
difluoride (PVDF) membrane (Millipore, Billerica, MA,
USA) carried blots and antibodies were transferred into
the Bio-Rad ChemiDoc XRS system, and then 200 µL of
Immobilon Western Chemiluminescent HRP Substrate
(Millipore) was added to cover the membrane surface. The
signals were captured and the intensity of the bands was
quantified using Image Lab Software (Bio-Rad, Shanghai,
China).
2.7. Validation in primary cells from a rat model with
adjuvant-induced arthritis
Male Sprague-Dawley rats (180–220 g) were purchased
from the Laboratory Animal Center (Chinese Academy of
Sciences, Shanghai, China). A rat model with arthritis was
induced by an intradermal injection of Freund’s complete
adjuvant supplemented with 10 mg/mL Mycobacterium
butyricum (Wei et al., 2013) in both the right hind paw and
the tail of the rats. Twenty-four days after immunization,
synovial tissues were carefully dissected and cut into
pieces, followed by treatment of 0.2% type II collagenase
(Chondrex, Redmond, WA, USA) at 37 °C for 2 h. The
cells were then washed and resuspended with RPMI 1640
containing 10% FBS in a humidified incubator at 37 °C
with 5% CO2. After washing and passaging, the primary
FLSs were obtained and transfected with pcDNA3.1, pcSNF5, shNC, or shSNF5 (the target sequence was replaced
by the Brg1 gene of rat). Thereafter, cell viability and
apoptosis were respectively measured by MTT assay and
flow cytometry.
2.8. Statistical analysis
All the experiments were repeated three times. The results
are presented as mean ± SD. Statistical analyses were
performed using GraphPad statistical software (GraphPad,
San Diego, CA, USA). One-way or two-way analysis
of variance (ANOVA) was done to compare the results
obtained from different groups. P < 0.05 was considered
statistically significant.
3. Results
3.1. Expression of SNF5 in different groups of MH7A
cells
The expression of SNF5 in all four groups mentioned above
was assessed through measurement of the specific mRNA
and protein levels of SNF5. Western blot analysis revealed
a significant increase (P < 0.001) in the SNF5 expression in
the pc-SNF5 group compared with the pcDNA3.1 group,

whereas a significant decrease (P < 0.001) was seen in
the SNF5 expression in the shSNF5 group in comparison
with that in the shNC group. SNF5 expression levels were
comparable (no significant difference, P > 0.05) between
the two control groups (pcDNA3.1 and shNC) (Figures 1A
and 1B).
3.2. Effects of SNF5 on cell proliferation
When compared to the respective controls, cell viability
analysis of MH7A cells in different groups revealed that
cell viability was significantly reduced at 2 days, 3 days,
and 4 days after transfection in the pc-SNF5 group (P <
0.05, P < 0.01, or P < 0.001), whereas in the shSNF5 group,
cell viability was increased significantly at 2 days, 3 days,
and 4 days after transfection (P < 0.05 or P < 0.001) (Figure
2).
3.3. Effects of SNF5 on cell apoptosis
Results of flow cytometry showed a maximum and
significant increase (P < 0.01) in the number of apoptotic
cells in the pc-SNF5 group (SNF5 overexpressed)
compared with the pcDNA3.1 group; the number of

Figure 1. Alteration of SNF5 expression in transfected cells.
MH7A cells were respectively transfected with pcDNA3.1, pcSNF5, shNC, or shSNF5. SNF5 expressions at both mRNA (A)
and protein (B) levels were then measured by qRT-PCR and
western blot analysis, respectively. Data presented are the means
of three independent experiments. Error bars indicate SD. *:
Significant difference compared with pcDNA3.1 group, ***: P <
0.001; #: significant difference compared with shNC group, ##: P
< 0.01. pc-SNF5, pcDNA3.1 containing Brg1 coding sequence;
shSNF5, short hairpin RNA against SNF5; shNC, negative control
of shSNF5; qRT-PCR, quantitative reverse-transcription PCR.
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Figure 2. Comparison of cell viability at different time intervals
among transfected cells. MH7A cells were respectively transfected
with pcDNA3.1, pc-SNF, shNC, or shSNF5. Cell viability was then
measured by MTT assay. Data presented are the means of three
independent experiments. Error bars indicate SD. *: Significant
difference compared with pcDNA3.1 group, *: P < 0.05, **: P <
0.01, ***: P < 0.001; #: significant difference compared with shNC
group, #: P < 0.05, ###: P < 0.001. pc-SNF5, pcDNA3.1 containing
Brg1 coding sequence; shSNF5, short hairpin RNA against SNF5;
shNC, negative control of shSNF5; MTT, 3-(4,5-dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide.

apoptotic cells in the shSNF5 group and the shNC group
was not significantly different (P > 0.05) (Figures 3A and
3B).
3.4. Effects of SNF5 on the expressions of p16 and JNK
pathway associated proteins
Western blot analysis revealed a significant decrease (P <
0.05, P < 0.01, or P < 0.001) in the phosphorylated levels
of the JNK pathway associated proteins, namely MKK4,
JNK, and c-Jun, in the pc-SNF5 group when compared
to the pcDNA3.1 group. However, the p16 expression
of the same cells in the pc-SNF5 group was significantly
increased (P < 0.001) when compared to the pcDNA3.1
group (Figure 4). Again, the effect of SNF5 knockdown on
phosphorylated levels of JNK pathway associated proteins
and the expression level of p16 was opposite to SNF5
overexpression when compared to the shNC group (P <
0.05, P < 0.01, or P < 0.001) (Figure 4).
3.5. Effects of SNF5 expressions on proliferation and
apoptosis of primary cells from a rat model with
adjuvant-induced arthritis
As with MH7A cells, the cell viability was markedly
reduced at 2 days, 3 days, and 4 days after transfection in
the pc-SNF5 group (P < 0.05 or P < 0.001), whereas in the
shSNF5 group, cell viability was increased significantly at

Figure 3. Comparison of cell apoptosis among transfected cells. (A) Percentage of apoptotic cells in the transfected cells. (B) Comparison
of apoptotic cells (in percentage) in the transfected cells. MH7A cells were respectively transfected with pcDNA3.1, pc-SNF, shNC, or
shSNF5. Cell apoptosis was then assessed by flow cytometry. Data presented are the means of three independent experiments. Error
bars indicate SD. *: Significant difference compared with pcDNA3.1 group, **: P < 0.01. pc-SNF5, pcDNA3.1 containing Brg1 coding
sequence; shSNF5, short hairpin RNA against SNF5; shNC, negative control of shSNF5.

538

WU et al. / Turk J Biol

Figure 4. Comparison of phosphorylated levels of MKK4, JNK, c-Jun, and expression levels of p16 in transfected cells. MH7A cells were
respectively transfected with pcDNA3.1, pc-SNF, shNC, or shSNF5. Protein expression was then assessed by western blot analysis. The
phosphorylated rate was expressed as the relative intensity of phosphorylated kinases/total kinases and the final results were normalized
by GAPDH. The expression fold of p16 was normalized by GAPDH. Data presented are the means of three independent experiments.
Error bars indicate SD. *: Significant difference compared with pcDNA3.1 group, *: P < 0.05, **: P < 0.01, ***: P < 0.001; #: significant
difference compared with shNC group, #: P < 0.05, ##: P < 0.01, ###: P < 0.001. pc-SNF5, pcDNA3.1 containing Brg1 coding sequence;
shSNF5, short hairpin RNA against SNF5; shNC, negative control of shSNF5; MKK4, mitogen activated protein kinase kinase 4.

2 days, 3 days, and 4 days after transfection (P < 0.05, P <
0.01, or P < 0.001) (Figure 5A). Meanwhile, cell apoptosis
was remarkably promoted by SNF5 overexpression (P <
0.001), as seen in Figure 5B.
4. Discussion
SNF5 (alternatively known as Ini1/Baf47/Smarcb1) as a
tumor suppressor is involved in various human cancers
(Sansam et al., 2005; Kadoch and Crabtree, 2015).
Malignant rhabdoid tumors (MRTs), a very aggressive
type of cancer that affects the pediatric population, occurs
mainly in the brain, kidneys, and soft tissues and is induced
by a specific biallelic mutation leading to the inactivation
of the SNF5 gene. Both clinical data (Kusafuka et al., 2004)
and animal experiments (in a murine model) supported
this (Capsoni et al., 2015). SNF5 is extensively distributed

in the central nervous system and in the mandibular area
of the first branchial arch (Kusafuka et al., 2004). Roberts
et al. concluded that homozygous silencing of the SNF5
gene led to the death of the mice during the embryonic
period. Additionally, although heterozygous silencing
does not kill the mice during the embryonic period
and the mice appeared to be normal, within 5 weeks of
age the heterozygous mice developed tumors consistent
with MRTs (Roberts et al., 2000). Thus, the importance
of SNF5 in the suppression of cancer is well established.
However, the role of SNF5 in other biological processes is
quite unexplored. Gresh et al. described that the normal
expression of SNF5 is essential to liver development and
glucose metabolism, and selective suppression of SNF5 in
the liver can lead to death in the perinatal period (Gresh
et al., 2005).
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Figure 5. Validation of the effect of SNF5 in primary cells of a rat model with adjuvant-induced arthritis. (A) Cell viability. (B) Relative
cell apoptosis. Cells were respectively transfected with pcDNA3.1, pc-SNF, shNC, or shSNF5. Cell viability and apoptosis were then
respectively measured by MTT assay and flow cytometry. Data presented are the means of three independent experiments. Error bars
indicate SD. *: Significant difference compared with pcDNA3.1 group, *: P < 0.05, **: P < 0.01, ***: P < 0.001; #: significant difference
compared with shNC group, #: P < 0.05, ###: P < 0.001. pc-SNF5, pcDNA3.1 containing Brg1 coding sequence of rat; shSNF5, short
hairpin RNA against SNF5 of rat; shNC, negative control of shSNF5; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide.

In this study, we also explored the possible alterations
in the molecular mechanism following SNF5 suppression
in RA, which led to the disease progression of RA. We
found that the expression of SNF5 was significantly
increased in MH7A human RA synovial cells transfected
with pc-SNF5 in comparison with cells transfected with
empty pcDNA3.1. Conversely, transfection of shSNF5 led
to a decrease of SNF5 expression.
Cell proliferation, measured by MTT assay, revealed
that overexpression of SNF5 (pc-SNF group) led to
significant suppression while SNF5 knockdown (shSNF5
group) led to a significant stimulation of cell proliferation
in the MH7A cells, strongly supporting the already
established role of SNF5 as a tumor suppressor. Meantime,
flow cytometric analysis also revealed that overexpression
of SNF5 in cells transfected with pc-SNF5 led to a
significant increase in the percentage of apoptotic cells,
along with a nonsignificant difference between the shNC
group and shSNF5 group.
The roles of p16 and proteins involved in the JNK
pathway in pathogenesis have already been well discussed
in several studies. Taniguchi et al. found that introduction
of p16 in the synovial fibroblast cells with the help of
adenoviral gene therapy led to the suppression of disease
progression in an animal model of RA (Taniguchi et al.,
1999). Murakami et al. concluded that p16, an inhibitor of
cell cycle progression, showed antiinflammatory effects on
rheumatoid synovial fibroblasts and its upregulation led to
inhibition of inflammatory cytokine production from the
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macrophages (Murakami et al., 2012). Ultimately, these
findings indicate a protective role of p16 in the suppression
of the disease progression of RA. In our study, we found that
the expression of p16 in SNF5-overexpressing cells (pcSNF5 group) was significantly upregulated in comparison
with the control (pcDNA3.1), and the expression of p16 in
SNF5-knockdown cells (shSNF5 group) was significantly
decreased in comparison with the control (shNC group).
These findings suggested that RA disease progression
was suppressed in the SNF5-overexpressing cells through
increased expression of favorable p16.
The ultimate outcome of disease progression of RA
is the destruction of the affected joints. Activation of
the JNK pathway has already been implicated in the
development of FLSs, which are mainly responsible for
the joint destruction in RA. Han described the role of the
JNK pathway in the pathogenesis of RA through the use
of a novel JNK pathway inhibitor and JNK knockout rat
model of adjuvant-induced arthritis (Han, 2001). It was
found that the novel JNK pathway inhibitor SP600125 not
only modestly decreased the paw edema in the rat model
of adjuvant-induced arthritis but also suppressed the
underlying joint destruction, as evidenced by radiographic
findings (Han, 2001).
In this study, we found that the phosphorylated
levels of JNK pathway associated proteins (MKK4, JNK,
and c-Jun) were all decreased significantly in the MH7A
cells with SNF5 overexpression (pc-SNF group) when
compared to the control (pcDNA3.1 group). Meanwhile,

WU et al. / Turk J Biol
the phosphorylated levels of MKK4, JNK, and c-Jun were
all increased markedly in cells with SNF5 knockdown
(shSNF5 group) when compared to the control (shNC
group).
Thus, we can conclude that SNF5, as a core component
of the chromatin remodeling complex (SWI/SNF), is a
known tumor suppressor and can also modify the course
of RA through its suppressive effects on RA FLSs. The

underlying molecular mechanism that promotes apoptosis
and suppresses proliferation of RA FLSs was mediated
through the upregulation of P16 and suppression of the
JNK pathway. Moreover, the effect of SNF5 was validated
in RA FLSs from a rat model of adjuvant-induced arthritis.
Further studies are required to predict the therapeutic
benefits of SNF5 as a novel drug target for the treatment
of RA.
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